| Trial ID: | L7352 |
| Source ID: | NCT03029351
|
| Associated Drug: |
Exenatide Extended Release For Inj Susp 2 Mg
|
| Title: |
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
|
| Acronym: |
1981
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03029351/results
|
| Conditions: |
Type2 Diabetes|Kidney Diseases
|
| Interventions: |
DRUG: Exenatide Extended Release for Inj Susp 2 MG|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change From Baseline in Urinary Albuminuria Levels, change from baseline in 24-hr urinary albuminuria (albumin/creatine) level at week 52 following Exenatide extended release OR placebo treatments, baseline and 52 weeks |
|
| Sponsor/Collaborators: |
Sponsor: University at Buffalo | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2017-01-10
|
| Completion Date: |
2019-07
|
| Results First Posted: |
2024-04-16
|
| Last Update Posted: |
2024-04-16
|
| Locations: |
Diabetes Endocrinology Research Center of WNY, Williamsville, New York, 14221, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03029351
|
